Arcadia Biosciences Q2 net loss widens - RKDA News | RalliesArcadia Biosciences Q2 net loss widens
R
RKDA• Outlook
- Company plans to introduce three additional new products in first half of 2027
Overview
- US wellness products producer's Q2 revenue was flat yr/yr due to inventory and shipping delays
- Q2 net loss widened on unrealized losses and PIPE financing valuation loss
- Company closed $4 mln private placement and ended Q2 with $4.2 mln in cash
Key details
| Metric | Actual |
|---|
| Q2 Revenue | $1.44 mln |
| Q2 Loss Per Share | $2.09 |
| Q2 Net Loss | $6.27 mln |
| Q2 Operating Expenses | $1.94 mln |
Result Drivers
- Inventory and shipping delays - Co said flat Q2 sales were primarily due to low inventory balances and longer-than-expected shipping times
- Lower SG&A expenses - SG&A fell by $1 mln in Q2, driven by lower employee costs and absence of M&A fees
•
